|
[1]PIAO XH, ZENG JY, YANG QF, et al.The safety and efficacy of Hepasphere microspheres in the treatm ent of advanced hepatocellular carcinoma[J].Chin J Interv Imaging Ther, 2018, 26 (11) :1732-1736. (in Chinese) 朴相浩, 曾健滢, 杨清峰, 等.Hepasphere载药微球栓塞治疗中晚期肝细胞肝癌的安全性及疗效分析[J].现代肿瘤医学, 2018, 26 (11) :1732-1736.
|
|
[2]WU J, YIN F, LUO GH, et al.Clinical effect and safety of transarterial chemoembolization combined with apatinib in treatment of advanced primary liver cancer[J].J Clin Hepatol, 2018, 34 (4) :775-778. (in Chinese) 武健, 尹芳, 罗贯虹, 等.经肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌的效果及安全性分析[J].临床肝胆病杂志, 2018, 34 (4) :775-778.
|
|
[3]TALAL A, AHMED M, ADB E, et al.Intra-arterial chemoembolization with hepasphere 50-100μm for patients with unresectable hepatocellular carcinoma:Initial experience in Egyptian Liver Hospital[J].Egypt J Radiol Nucl Med, 2015, 46 (5) :957-965.
|
|
[4]FORNER A, GILABERT M, BRUIX J, et al.Treatment of intermediate-stage hepatocellular carcinoma[J].Nat Rev Clin Oncol, 2014, 11 (9) :525-535.
|
|
[5]TERZI E, GOLFIERI R, PISCAGLIA F, et al.Response rate and clinical outcome of HCC afterfirst and repeated cTACEperformed“on demand”[J].J Hepatol, 2012, 57 (6) :1258-1267.
|
|
[6]MALAGARI K, POMONI M, MOSCHOURIS H, et al.Chemoembolization withdoxorubicin-eluting beads for unresectable hepatocellular car-cinoma:Five-year survival analysis[J].Cardiovasc Intervent Radiol, 2012, 35 (5) :1119-1128.
|
|
[7]CHEN QW, YING HF, GAO S, et al.Radiofrequency ablation plus chemoembolization versusradiofrequency ablation alone for hepatocellular carcinoma:A systematic review and metaanalysis[J].Clin Res Hepatol Gastroenterol, 2016, 40 (3) :309-314.
|
|
[8]GEEST LG, MEER S, SCHRIER, et al.Survival in relation to hospitaltype after resection or sorafenib treatment for hepatocellularcarcinoma in the Netherlands[J].Clin Res Hepatol Gastroenterol, 2015, 39 (6) :725-735.
|
|
[9]MARTIN R, GELLER D, ESPAT J, et al.Safety and efficacy of trans arterial chemoembolizationwith drug-eluting beads in hepatocellular cancer:A systematicreview[J].Hepatogastroenterology, 2012, 59 (113) :255-260.
|
|
[10]CHEN G, ZHANG D, YING YC, et al.Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma[J].J Zhejiang Univ:Med Sci, 2017, 46 (1) :44-51. (in Chinese) 陈刚, 张鼎, 应亚草, 等.国产载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[J].浙江大学学报:医学版, 2017, 46 (1) :44-51.
|
|
[11]CHI Q, ZHANG LL, LIU B, et al.Efficacy of epirubicin combined with lipiodol or Hepasphere loaded microspheres in the treatment of TACE in patients with hepatocellular carcinoma[J].Mod Oncol, 2018, 26 (13) :2090-2093. (in Chinese) 池琦, 张玲玲, 刘彬, 等.表柔比星分别联合碘油与Hepasphere载药微球对肝癌患者TACE的疗效分析[J].现代肿瘤医学, 2018, 26 (13) :2090-2093.
|
|
[12]FERRER P, PARRA C, ESTEBAN E, et al.Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TA-CE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma[J].Radiologia, 2011, 53 (3) :246-253.
|
|
[13]HUANG YJ, LING YZ, QIN ZL, et al.Evaluation of the effect of HepaSphere transmitted microspheres in the treatment of primary liver cancer[J].Clin Med, 2018, 38 (1) :35-36. (in Chinese) 黄英杰, 凌永志, 秦梓良, 等.HepaSphere载药微球治疗原发性肝癌的效果评价[J].临床医学, 2018, 38 (1) :35-36.
|
|
[14]LAMMER J, MALAGARI K, VOGL T, et al.Prospective randomized study of Doxorubicin-Eluting-Bead embolization in the treatment of hepatocellular carcinoma:Results of the PRE-CISION V study[J].Cardiovasc Intervent Radiol, 2010, 33 (1) :41-52.
|
|
[15]LENCIONI R, MALAGARI K, VOGL T, et al.A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization[J].Hepatology, 2009, 20 (2) :s70-s71.
|
|
[16]MALAGRI K, POMONI M, KELEKIS A, et al.Prospective randomized comparison of chemoembolization with doxorubicineluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J].Cardiovasc Intervent Radiol, 2010, 33 (3) :541-551.
|
|
[17]SACCO R, BARGELLINI I, BERTIN M, et al.Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma[J].J Vasc Interv Radiol, 2011, 22 (11) :1545-1552.
|
|
[18]SONG MJ, CHUN HJ, SONG DS, et al.Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma[J].J Hepatol, 2012, 57 (6) :1244-1250.
|
|
[19]WIGGERMANN P, SIERON D, BROSCHE C, et al.Transarterial chemoembolization of Child-A hepatocellular carcinoma:Drug-eluting bead TACE (DEB TACE) vs.TACE with Cisplatin/Lipiodol (cTACE) [J].Med Sci Monit, 2011, 17 (4) :189-195.
|
|
[20]YOU JX, WANG JB, AI ST, et al.TACE by using microspheres and lipiodol for the treatment of hepatocellular carcinoma:Analysis of short-term efficacy[J].J Intervent Radiol, 2017, 26 (6) :531-534. (in Chinese) 游建雄, 王精兵, 艾松涛, 等.微球联合碘油栓塞治疗肝癌的近期疗效分析[J].介入放射学杂志, 2017, 26 (6) :531-534.
|
|
[21]DHANASEKARAN K, KOOBY DA, STALEY CA, et al.Comparison of conventional transarterial chemoembolization (TA-CE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) [J].J Surg Onc, 2010, 101 (6) :476-480.
|
|
[22]GOLFIERI R, GIAMPALMA E, RENZULLI M, et al.Randomised controlled trial ofdoxorubicin-eluting beads vs conventional chemoembolisationfor hepatocellular carcinoma[J].Br J Cancer, 2014, 111 (2) :255-264.
|
|
[23]MEMON K, KULIK L, LEWANDOWSKI RJ, et al.Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times[J].Gastroenterology, 2011, 141 (2) :526-535, e522.
|
|
[24]OU SQ, CHEN ZY, MA YL, et al.Meta-analysis of comparative study between doxoruibcin-eluting beads and conventional transarterial hemoeobolization for hepatocellular carcinoma[J].Chin J Interv Imaging Ther, 2011, 11 (11) :712-716. (in Chinese) 欧盛秋, 陈祖毅, 马亦龙, 等.阿霉素载药微球与传统的碘化油经导管动脉化疗栓塞术治疗原发性肝癌疗效的Meta分析[J].中国介入影像与治疗学, 2011, 11 (11) :712-716.
|
|
[25]MALAGARI K, ALEXOPOULOU E, CHATZIMICHAIL K, et al.Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments:Midterm results of doxorubicin-loaded DC bead[J].Abdom Imaging, 2008, 33 (5) :512-519.
|
|
[26]QI XS, ZHAO Y, LI HY, et al.Management of hepatocellular carcinoma:an overview of major findings from meta-analyses[J].Oncotarget, 2016, 7 (23) :34703-34751.
|
|
[27]GAO S, YANG Z, ZHENG Z, et al.Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma:A meta analysis[J].Hepatogastroenterology, 2013, 60 (126) :813-820.
|
|
[28]HAN SL, ZHANG XP, ZOU LL, et al.Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma?A Meta-Analysis[J].PLo S One, 2014, 9 (8) :e1022686.
|
|
[29]HUANG K, ZHOU, WANG R, et al.Doxorubicin-elutingbeads versus conventional transarterial chemoembolization forthe treatment of hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2014, 29 (5) :920-925.
|
|
[30]CHEN P, YUAN P, CHEN B, et al.Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma:A systematic review and meta-analysis[J].Clin Res Hepatol Gastroenterol, 2017, 41 (1) :75-85.
|
DownLoad: